Regulatory mechanisms of PD-1/PD-L1 in cancers

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immune evasion is a critical factor in cancer progression, with cancer cells exploiting immune checkpoint pathways to suppress anti-tumor responses.
• The programmed cell death protein 1 (PD-1) and its ligands (PD-L1) are key immune checkpoint molecules that negatively regulate T cell activity and promote immune tolerance.
• Cancer cells leverage the PD-1/PD-L1 axis to achieve immune escape, hindering the body's natural defenses against tumor growth.

Purpose of the Study:

• To comprehensively review the roles of PD-1/PD-L1 signaling in human autoimmune diseases and cancers.
• To summarize the regulatory mechanisms governing PD-1 and PD-L1 expression and activity in cancer.
• To review clinical progress on anti-PD-1/PD-L1 therapies and their combination strategies for enhanced anti-tumor immunity.

Main Methods:

• Review of existing literature on PD-1/PD-L1 signaling in cancer and autoimmune diseases.
• Analysis of genetic, epigenetic, post-transcriptional, and post-translational regulatory mechanisms of PD-1/PD-L1.
• Summary of clinical trial data on PD-1/PD-L1 blockade therapies.

Main Results:

• The PD-1/PD-L1 pathway is a significant mechanism for cancer immune evasion.
• Various regulatory mechanisms control PD-1/PD-L1 expression and function in cancer cells.
• Blockade of PD-1/PD-L1 with antibodies effectively restores T cell activity and enhances anti-tumor immunity, showing clinical success.

Conclusions:

• Targeting the PD-1/PD-L1 axis is a promising therapeutic strategy for cancer treatment.
• Understanding the regulatory mechanisms of PD-1/PD-L1 can lead to the development of novel tumor markers.
• Combination therapies involving PD-1/PD-L1 blockade offer potential for improved anti-tumor effects and overcoming treatment resistance.